Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL

Blood

Volumn 106, Issue 10, 2005, Pages 3383-3385

  Moskowitz, Craig H ^a   Zelenetz, Andrew D ^a   Kewalramani, Tarun ^a   Hamlin, Paul ^a   Lessac Chenen, Simone ^a   Houldsworth, Jane ^a   Olshen, Adam ^a   Chaganti, Raju ^a   Nimer, Stephen ^a   Teruya Feldstein, Julie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BIOPSY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG MEGADOSE; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SALVAGE THERAPY; TISSUE MICROARRAY; TREATMENT OUTCOME;

EID: 27744563281     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1603     Document Type: Article

References (14)

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
2. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
4. Hans CP,Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
5. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplantation-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3776-3785.
6. Moskowitz CH, Nimer SD, Glassman JR, et al. The international prognostic index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant. 1999;23:561-567.
7. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood. 2000;96:2399-2404.
8. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102:1989-1996.
9. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14(suppl 1):i5-10.
10. Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol. 2002;33:968-974.
11. Teruya-Feldstein J, Donnelly GB, Goy A, et al. MUC-1 mucin protein expression in B-cell lymphomas. Appl Immunohistochem Mol Morphol. 2003;11:28-32.
12. Houldsworth J, Olshen AB, Cattoretti G, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood. 2004;103:1862-1868.
13. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991-9996.
14. Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann Oncol. 1999;10:13-19.